IDSA Letter to WHO on Prioritizing Antimicrobial Resistant Pathogens (PDF)
IDSA reached out to World Health Organization Director Dr. Margaret Chan on the need to prioritize antimicrobial resistant pathogens as it develops its Global R&D Priority Pathogens List.
IDSA Statement to Senate HELP Committee on Laboratory Developed Tests (PDF)
IDSA provided a statement at the Senate Health, Education, Labor and Pensions (HELP) Committee hearing on laboratory developed tests (LDTs) regarding the important role they play in infectious disease clinical care, public health, and on the potential impact proposed new regulations may have on innovation and patient access to testing.
IDSA Letter Urges Congress to Provide 2017 Funding for ID Programs (PDF)
In a letter to leaders of the House and Senate spending committees, IDSA urged support for federal infectious diseases programs. The letter also asked appropriators to complete the funding process before the end of the year.
IDSA Leads Organizations in Advocacy for Implementation of NIH Physician Scientist Workforce Recommendations (PDF)
IDSA was joined by 35 other health groups in a letter to NIH Director Francis Collins requesting an update on efforts to bolster the physician-scientist workforce.
IDSA Engages House Subcommittee Ahead of Hearing on Antibiotic Resistance (PDF)
In advance of a hearing on federal efforts to address antibiotic resistance, IDSA wrote to leaders of the Subcommittee to urge support for implementation of the National Action Plan for Combating Antibiotic-Resistance Bacteria. The letter placed particular emphasis on antibiotic stewardship, incentives to spur R&D, ID workforce challenges, and the need for increased funding for federal AR programs.
IDSA Zika Vote Statement (PDF)
IDSA urges Congress to pass the strongest emergency bill possible to combat Zika and to reject efforts to fund the Zika response at the expense of equally critical health funding.
IDSA, ASM, and PASCV Letter to FDA on LDTs (PDF)
IDSA, ASM and the Pan-American Society for Clinical Virology urge FDA to consider the vital role of lab developed tests in rapidly diagnosing and appropriately treating infectious diseases.
PACCARB Press Release
Recommendations from the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria reflect IDSA input.
1 of 8
CDC Advises Hospitals to Alert Patients at Risk from Contaminated Heater-Cooler Devices Used during Cardiac Surgery
The Centers for Disease Control and Prevention (CDC) is advising hospitals to notify patients who underwent open-heart (open-chest) surgery involving a Stöckert 3T heater-cooler that the device was potentially contaminated, possibly putting patients at risk for a life threatening infection.
Zika Virus Infection Related to the Ongoing Investigation of Local Mosquito-borne Zika Virus Transmission in Miami-Dade County, Florida
FDA issues final rule on safety and effectiveness of antibacterial soaps
FDA Advises Testing for Zika Virus in All Donated Blood in the US
August Update: Interim Guidance: Infants with Possible Congenital Zika Virus Infection
July 2016 Safety Labeling Changes posting includes 52 products
FDA approves first generic version of widely used influenza drug
Updated Interim Zika Clinical Guidance for Pregnant Women and Data on Contraceptive Use to Decrease Zika-affected Pregnancies
Read More >>
From the PresidentUN Declaration to Fight AMRCountdown to IDWeek 2016Journal Club
>> Read More
The Infectious Diseases Society of America (IDSA) welcomes the action taken by Congress to prevent a government shutdown and provide $1.1 billion for responses to the continuing spread of the Zika virus. The full and continuous operation of Federal agencies, including the Centers for Disease Control and Prevention and the National Institutes of Health, is critical to our nation’s safety and wellbeing. Additionally, the overdue resources the bill provides for global and domestic Zika responses must be put to work immediately.
Infectious Diseases Society of America (IDSA) Vice President Paul Auwaerter, MD, MBA, FIDSA and Treasurer Helen Boucher, MD, FIDSA will join world leaders gathering tomorrow for an historic United Nations (UN) General Assembly meeting on one of the most urgent public health crises facing our world today—antimicrobial resistance (AMR). More than 500 IDSA members with expertise in AMR stand behind Drs. Auwaerter and Boucher on a petition that will be sent to the UN today in support of a coordinated global response to this global threat. Tomorrow’s high level meeting represents a significant opportunity to drive the action needed to effectively stem the tide of AMR.
The Infectious Diseases Society of America (IDSA) is pleased that the Senate Health, Education, Labor and Pensions (HELP)” Committee has scheduled the hearing, “Laboratory Testing in the Era of Precision Medicine,” for September 20, 2016. Infectious diseases (ID) physicians rely upon diagnostics—both laboratory developed tests (LDTs) and commercial tests—to identify infecting pathogens and their antimicrobial susceptibility and to monitor response to treatment.
All patients beginning hepatitis C (HCV) treatment using direct acting antiviral (DAA) therapies should be assessed for hepatitis B (HBV), according the American Association for the Study of Liver Diseases/Infectious Diseases Society of America Guidance Panel, which provides up-to-date guidance on the treatment of hepatitis C on its website, HCVguidelines.org.
>>Read More From the PresidentDon't Miss These IDSA Guidelines UpdatesIDSA Honors 111 Distinguished Physicians, Scientists with FIDSAIDWeek 2016: Not-to-Miss Sessions Featuring the Latest on the Zika OutbreakJournal Club
Tuberculosis (TB) is a leading killer of people with HIV, and providing therapy for both illnesses simultaneously saves lives - according to new guidelines on the treatment of drug-susceptible TB developed jointly by the American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA). Treatment of TB in the presence of HIV infection is one of several special situations addressed in the new guidelines, published today in the journal Clinical Infectious Diseases.
1 of 7
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2016 Infectious Diseases Society of America